IL3RA and acute myeloid leukemia: Qin et al. reported a new methodology to improve the quality of targeting domains included into the structure of CAR-T: using this approach, they identified and characterized domains specific for CD123 and incorporated these domains into CAR-T exhibiting potent T cell activation and cytolysis of CD123-expressing leukemic cells, inducing complete durable remission in two AML xenograft models [114].